Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralise the Omicron variant.
Two doses, however, show 'significantly reduced neutralisation titers' - which means the concentration of antibodies is lower than with three jabs. READ MORE:PMQS LIVE as Boris Johnson faces grilling over No 10 Christmas party following video leak Early data indicates that a third dose of the vaccine increases the antibodies neutralising Omicron by 25-fold compared to two doses, according to Pfizer and BioNTech, giving a high level of protection.
However, two doses may still induce protection against severe disease, the companies confirmed this morning (December 8). The companies are continuing to development a
Read more on manchestereveningnews.co.uk